WO2005020982A3 - Using selective antagonists of persistent sodium current to treat neurological disorders and pain - Google Patents

Using selective antagonists of persistent sodium current to treat neurological disorders and pain Download PDF

Info

Publication number
WO2005020982A3
WO2005020982A3 PCT/US2004/028077 US2004028077W WO2005020982A3 WO 2005020982 A3 WO2005020982 A3 WO 2005020982A3 US 2004028077 W US2004028077 W US 2004028077W WO 2005020982 A3 WO2005020982 A3 WO 2005020982A3
Authority
WO
WIPO (PCT)
Prior art keywords
sodium current
neurological disorders
pain
persistent sodium
selective antagonists
Prior art date
Application number
PCT/US2004/028077
Other languages
French (fr)
Other versions
WO2005020982A2 (en
Inventor
George R Ehring
Joseph S Adorante
John E Donello
Thomas Malone
Larry A Wheeler
Scott M Whitcup
Original Assignee
Allergan Inc
George R Ehring
Joseph S Adorante
John E Donello
Thomas Malone
Larry A Wheeler
Scott M Whitcup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04782536A priority Critical patent/EP1658065A2/en
Priority to AU2004268633A priority patent/AU2004268633B2/en
Priority to BRPI0413920-8A priority patent/BRPI0413920A/en
Priority to CA002537088A priority patent/CA2537088A1/en
Priority to JP2006524922A priority patent/JP2007504165A/en
Application filed by Allergan Inc, George R Ehring, Joseph S Adorante, John E Donello, Thomas Malone, Larry A Wheeler, Scott M Whitcup filed Critical Allergan Inc
Publication of WO2005020982A2 publication Critical patent/WO2005020982A2/en
Publication of WO2005020982A3 publication Critical patent/WO2005020982A3/en
Priority to AU2008207539A priority patent/AU2008207539A1/en
Priority to AU2008207538A priority patent/AU2008207538A1/en
Priority to AU2008207560A priority patent/AU2008207560A1/en
Priority to AU2008207547A priority patent/AU2008207547B2/en
Priority to AU2008207631A priority patent/AU2008207631A1/en
Priority to AU2008207634A priority patent/AU2008207634A1/en
Priority to AU2008207633A priority patent/AU2008207633A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

The present invention provides uses of compounds as medicaments for treating neurological disorders and chronic pain in mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
PCT/US2004/028077 2003-08-29 2004-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain WO2005020982A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP04782536A EP1658065A2 (en) 2003-08-29 2004-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2004268633A AU2004268633B2 (en) 2003-08-29 2004-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
BRPI0413920-8A BRPI0413920A (en) 2003-08-29 2004-08-27 selective persistent sodium current antagonists to treat neurological disorders and pain
CA002537088A CA2537088A1 (en) 2003-08-29 2004-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
JP2006524922A JP2007504165A (en) 2003-08-29 2004-08-27 Use of selective sodium current selective antagonists for the treatment of neurological diseases and pain
AU2008207539A AU2008207539A1 (en) 2003-08-29 2008-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207547A AU2008207547B2 (en) 2003-08-29 2008-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207560A AU2008207560A1 (en) 2003-08-29 2008-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207538A AU2008207538A1 (en) 2003-08-29 2008-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207631A AU2008207631A1 (en) 2003-08-29 2008-08-29 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207634A AU2008207634A1 (en) 2003-08-29 2008-08-29 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
AU2008207633A AU2008207633A1 (en) 2003-08-29 2008-08-29 Using selective antagonists of persistent sodium current to treat neurological disorders and pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49890203P 2003-08-29 2003-08-29
US49890003P 2003-08-29 2003-08-29
US60/498,900 2003-08-29
US60/498,902 2003-08-29

Publications (2)

Publication Number Publication Date
WO2005020982A2 WO2005020982A2 (en) 2005-03-10
WO2005020982A3 true WO2005020982A3 (en) 2005-08-25

Family

ID=34278629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/028077 WO2005020982A2 (en) 2003-08-29 2004-08-27 Using selective antagonists of persistent sodium current to treat neurological disorders and pain

Country Status (6)

Country Link
EP (1) EP1658065A2 (en)
JP (1) JP2007504165A (en)
AU (7) AU2004268633B2 (en)
BR (1) BRPI0413920A (en)
CA (1) CA2537088A1 (en)
WO (1) WO2005020982A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
JP2009510198A (en) * 2005-09-26 2009-03-12 インヴィトロジェン コーポレーション Purple laser-excitable dye and method of using the same
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1182193A1 (en) * 1999-04-09 2002-02-27 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
US20020077297A1 (en) * 2000-11-22 2002-06-20 Adorante Joseph S. High-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1182193A1 (en) * 1999-04-09 2002-02-27 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
US20020077297A1 (en) * 2000-11-22 2002-06-20 Adorante Joseph S. High-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"AsInex Express Gold Collection", 23 April 2003, ASINEX, MOSCOW, 123182, RUSSIA *
DATABASE CHEMCATS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002315431, retrieved from STN *
NIELSEN K J ET AL: "SOLUTION STRUCTURE OF MU-CONOTOXIN PIIIA, A PREFERENTIAL INHIBITOR OF PERSISTENT TETRODOTOXIN-SENSITIVE SODIUM CHANNELS", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 27247 - 27255, XP008041937, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2008207547A1 (en) 2008-09-18
BRPI0413920A (en) 2006-10-24
AU2008207634A1 (en) 2008-09-25
AU2008207560A1 (en) 2008-09-18
AU2008207539A1 (en) 2008-09-18
AU2004268633B2 (en) 2010-11-18
CA2537088A1 (en) 2005-03-10
AU2004268633A1 (en) 2005-03-10
EP1658065A2 (en) 2006-05-24
AU2008207633A1 (en) 2008-09-25
AU2008207547B2 (en) 2011-08-11
AU2008207538A1 (en) 2008-09-18
WO2005020982A2 (en) 2005-03-10
JP2007504165A (en) 2007-03-01

Similar Documents

Publication Publication Date Title
BG110174A (en) Substituted arylpyrazines
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2004108157A3 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
IN2006KO01346A (en)
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
WO2005019266A3 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2003026479A3 (en) Methods of suppressing microglial activation
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
DE60038290D1 (en) OPIOIDANT AGONIC COMPOSITION FOR INCREASING THE ANALGETIC EFFICACY OF TRAMADOL AND REDUCING THEIR SIDE EFFECTS
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
RS74403A (en) Derivatives of n-(arylslfonyl)beta- aminoacids comprising a supstituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
MXPA06002726A (en) Methods for identifying improved, non-sedating alpha-2 agonists.
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
BR0314488A (en) Compound, pharmaceutical composition and treatment methods
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
WO2005079766A3 (en) Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2005065183A3 (en) Mitotic kinesin inhibitors
ME00571A (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004782536

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2537088

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006524922

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004268633

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004268633

Country of ref document: AU

Date of ref document: 20040827

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004268633

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004782536

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413920

Country of ref document: BR